Giorgio Vittorio Scagliotti, MD | Authors

Gemcitabine/Cisplatin as Induction Therapy for Stage IIIA N2 Non–Small-Cell Lung Cancer

July 01, 2000

Because the majority of patients with stage IIIA N2 non–small-cell lung cancer (NSCLC) ultimately die of distant metastases, recent efforts to improve their intermediate- and long-term survival have focused on neoadjuvant